Pharmicell Valuation Multiples

Pharmicell Overview

About Pharmicell

Pharmicell Co Ltd is a biotechnology company, engages in the manufacturing of biopharmaceutical medicines in South Korea. Its biopharmaceutical business engages in the development and manufacture of stem cell therapeutic drugs and stem cell-based cosmetics and others. Its products under development include mesenchymal stem cell products, such as Cellgram_AMI, a heart disease drug; Cellgram_IS and Cellgram_SCI, which are brain/nerve disorder drugs; Cellgram_Lung, a pulmonary disease drug; Cellgram_LC, a liver disease drug; and Cellgram_ED and Cellgram_CLI for the treatment of graft-versus-host disease, kidney transplant, impotence, and critical lower limb ischemia.

Founded

1968

HQ

Employees

N/A

Website

pharmicell.com

Sectors

BiopharmaceuticalsBioTech

Financials (LTM)

Revenue: $84M

EBITDA: $29M

EV

$686M

Valuation Multiples

Multiples.vc

Start free trial

Pharmicell Financials

Pharmicell reported last 12-month revenue of $84M and EBITDA of $29M.

In the same LTM period, Pharmicell generated $39M in gross profit, $29M in EBITDA, and $29M in net income.

Pharmicell P&L

In the most recent fiscal year, Pharmicell reported revenue of $43M and EBITDA of $6M.

Pharmicell expects next 12-month revenue of XXX and NTM EBITDA of XXX

Pharmicell Stock Performance

Pharmicell has current market cap of $706M, and enterprise value of $686M.

Pharmicell's stock price is $11.76.

Pharmicell Valuation Multiples

Pharmicell trades at 8.2x EV/Revenue multiple, and 23.5x EV/EBITDA.

Pharmicell Financial Valuation Multiples

As of March 20, 2026, Pharmicell has market cap of $706M and EV of $686M.

Equity research analysts estimate Pharmicell's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

Pharmicell has a P/E ratio of 24.2x.

Pharmicell Margins & Growth Rates

Pharmicell's revenue in the last 12 month grew by 42%.

Pharmicell's rule of 40 is 77% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Pharmicell's rule of X is 140% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

Pharmicell Public Comps

See public comps and valuation multiples for other Biopharmaceuticals comps.

Pharmicell M&A Activity

Pharmicell acquired XXX companies to date.

Last acquisition by Pharmicell was on XXXXXXXX, XXXXX. Pharmicell acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).

Pharmicell Investment Activity

Pharmicell invested in XXX companies to date.

Pharmicell made its latest investment on XXXXXXXX, XXXXX. Pharmicell invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).